ELIANA included pediatric and young adults with relapsed/refractory B cell acute lymphoblastic leukemia (ALL). CAR T cells were engineered to react to CD19, a protein that is common on B cells. 83% of pts achieved a CR or CR with incomplete blood count recovery within 3 mos of infusion. In the study, 49% of pts experienced grade 3-4 cytokine release syndrome. Within 8 wks of Tx, 18% of pts experienced grade 3-4 neurologic events. (Kymriah [tisagenlecleucel] Prescribing information, Novartis, August 2017)